Top Story

Lanreotide shows promise in patients with pancreatic neuroendocrine tumors

January 28, 2015

Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a subgroup analysis of the CLARINET study presented at the Gastrointestinal Cancers Symposium.

The randomized, double blind CLARINET study included patients with metastatic grade 1 or grade 2 (Ki-67 <10%) non-functioning enteropancreatic neuroendocrine tumors. Patients underwent first-line treatment with 120 mg lanreotide (Somatuline Depot, Ipsen), a somatostatin analog, or placebo every 4 weeks for 96 weeks. Lanreotide was administered by deep subcutaneous injection.

In the Journals

Exam of numerous tissues shows no significant difference in staging thin melanomas

January 27, 2015
The optimal number of sections to assess in staging thin melanomas without ulceration was three, with no significant difference in examining numerous tissue sections…
In the Journals

Intraosseous lesions may be linked with osteochondromas

January 27, 2015
Recently published data established a tentative link between patients exhibiting multiple osteochondromas and intraosseous chondroid lesions.Investigators…
In the Journals

Bevacizumab-induced hypertension associated with improved OS, PFS in glioblastoma

January 27, 2015
Patients with recurrent glioblastoma who experienced bevacizumab-induced hypertension demonstrated prolonged OS and PFS, according to study results.The findings suggest…
Aaron Tobian, MD, PhD In the Journals

Platelet transfusions associated with increased risk for death in HIT, TTP

January 27, 2015
Platelet transfusions are frequently used in patients with thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura and heparin-induced thrombocytopenia…
More News Headlines »
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »